SCHN Key Statistics, Chart & Performance
The current stock price of SCHN is 33.2 USD. In the past month the price decreased by -2.78%. In the past year, price increased by 2.88%.
SCHN Latest News, Press Relases and Analysis
SCHN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| NUE | NUCOR CORP | 21.94 | 36.50B | ||
| STLD | STEEL DYNAMICS INC | 22.23 | 24.51B | ||
| RS | RELIANCE INC | 19.87 | 14.61B | ||
| CMC | COMMERCIAL METALS CO | 20.25 | 7.08B | ||
| CLF | CLEVELAND-CLIFFS INC | N/A | 7.43B | ||
| HCC | WARRIOR MET COAL INC | 97.86 | 4.12B | ||
| AMR | ALPHA METALLURGICAL RESOURCE | N/A | 2.05B | ||
| WS | WORTHINGTON STEEL INC | 14.3 | 1.72B | ||
| METC | RAMACO RESOURCES INC-A | N/A | 1.04B | ||
| METCB | RAMACO RESOURCES INC-B | N/A | 825.66M | ||
| RYI | RYERSON HOLDING CORP | N/A | 738.58M | ||
| MTUS | METALLUS INC | 35.98 | 704.30M |
Related stock screener links
About SCHN
Company Profile
Schnitzer Steel Industries, Inc. engages in the recycling of ferrous and nonferrous scrap metal and manufacture of finished steel products. The company is headquartered in Boston, Massachusetts and currently employs 3,471 full-time employees. The firm is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The firm also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).
Company Info
SCHNITZER STEEL INDS INC-A
22 Boston Wharf Road, 7Th Floor
Boston MASSACHUSETTS 97201 US
CEO: Tamara L. Lundgren
Employees: 3471
Phone: 15032249900.0
SCHNITZER STEEL INDS INC-A / SCHN FAQ
What does SCHN do?
Schnitzer Steel Industries, Inc. engages in the recycling of ferrous and nonferrous scrap metal and manufacture of finished steel products. The company is headquartered in Boston, Massachusetts and currently employs 3,471 full-time employees. The firm is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The firm also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).
What is the current price of SCHN stock?
The current stock price of SCHN is 33.2 USD. The price decreased by -0.57% in the last trading session.
What is the dividend status of SCHNITZER STEEL INDS INC-A?
SCHNITZER STEEL INDS INC-A (SCHN) has a dividend yield of 2.52%. The yearly dividend amount is currently 0.
What is the ChartMill rating of SCHNITZER STEEL INDS INC-A stock?
SCHN has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for SCHNITZER STEEL INDS INC-A?
SCHNITZER STEEL INDS INC-A (SCHN) operates in the Materials sector and the Metals & Mining industry.
Can you provide the market cap for SCHNITZER STEEL INDS INC-A?
SCHNITZER STEEL INDS INC-A (SCHN) has a market capitalization of 906.73M USD. This makes SCHN a Small Cap stock.
SCHN Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SCHN. When comparing the yearly performance of all stocks, SCHN is one of the better performing stocks in the market, outperforming 74.13% of all stocks.
SCHN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SCHN. SCHN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SCHN Financial Highlights
Over the last trailing twelve months SCHN reported a non-GAAP Earnings per Share(EPS) of 0.87. The EPS decreased by -88.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.34% | ||
| ROA | 0.56% | ||
| ROE | 1.11% | ||
| Debt/Equity | 0.37 |
SCHN Forecast & Estimates
9 analysts have analysed SCHN and the average price target is 35.7 USD. This implies a price increase of 7.53% is expected in the next year compared to the current price of 33.2.
For the next year, analysts expect an EPS growth of -87.36% and a revenue growth -15.3% for SCHN